A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that ...

Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, ...

门脉性肺动脉高压（portopulmonary hypertension，PoPH）是门静脉高压的一种常见并发症，目前被归为肺动脉高压（pulmonary arterial ...

Aims Pulmonary hypertension (PHT) appears to be very common in heart failure with preserved ejection fraction but details on ...

Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...

The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg ...

Long-term exposure to high levels of air pollution can accelerate the progression of both chronic respiratory diseases and pulmonary hypertension.

After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after a year of muscular performance and its ...

Merck’s new pulmonary arterial hypertension (PAH) medication has posted another batch of promising clinical trial data, ...

Rx, a leading digital medicine and biomarker company driving healthcare through pulmonary innovation, today announced that it ...